Clinical impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib or trifluridine/tipiracil as later-line.

Authors

null

Hiromichi Nakajima

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Hiromichi Nakajima , Shota Fukuoka , Toshikazu Moriwaki , Toshiki Masuishi , Atsuo Takashima , Yosuke Kumekawa , Takeshi Kajiwara , Kentaro Yamazaki , Masato Komoda , Akitaka Makiyama , Tadamichi Denda , Yukimasa Hatachi , Takeshi Suto , Naotoshi Sugimoto , Masanobu Enomoto , Toshiaki Ishikawa , Tomomi Kashiwada , Eiji Oki , Masahiko Gosho , Yasuhiro Shimada

Organizations

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan, Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan, Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan, Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan, Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan, Chiba Cancer Center, Chiba, Japan, Department of Medical Oncology, Takarazuka City Hospital, Takarazuka, Japan, Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan, Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan, Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan, Department of Specialized Surgeries, Tokyo Medical and Dental University, Tokyo, Japan, Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan, Kyushu University, Fukuoka, Japan, Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, Clinical Oncology Division, Kochi Health Sciences Center, Kochi, Japan

Research Funding

Other Foundation
Japanese Society for Cancer of the Colon and Rectum

Background: In the recent years, primary tumor location (PTL) is considered as an important prognostic and predictive factor in first-line treatment of mCRC. Although regorafenib (REG) and trifluridine/tipiracil (TFTD) have been available recently, the prognostic value of PTL in later-line with these agents is not well understood. TFTD improved survival regardless of PTL in the RECOURSE trial, while REG did not show survival benefit in the patients (pts) with rectal cancer in the CORRECT trial. Methods: We retrospectively evaluated pts with mCRC who were registered in a multicenter observational study (the REGOTAS study). The main inclusion criteria were ECOG PS of 0–2, refractory or intolerant to fluoropyrimidines, oxaliplatin, irinotecan, and anti-VEGF and anti-EGFR therapy (if KRAS wild type), and no prior use of REG and TFTD. The impact of PTL on overall survival (OS) were evaluated using Cox proportional hazards models based on baseline characteristics and propensity score matching. Results: A total of 550 pts (223 pts in the REG group, 327 pts in the TFTD group; 122 pts in the right-sided, 428 pts in the left-sided) were included in this study. Although the right-sided pts was significantly shorter OS compared with the left-sided pts by univariate analysis (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.63-0.99, P = 0.04), multivariate analysis revealed that PTL was not an independent prognostic factor (HR 0.88, 95% CI 0.69-1.1, P = 0.26). The similar results were obtained in each treatment group. In subgroup analysis according to PTL, OS were comparable between REG and TFTD groups regardless of PTL (HR 0.93, 95% CI 0.62-1.39 in the right-sided; HR 1.08, 95% CI 0.83-1.39 in the left-sided [excluding rectum]; and HR 1.01, 95% CI 0.62-1.62 in the rectal cancer pts). These results were similar in sensitivity analysis using propensity score-matching. Conclusions: In the present study, PTL is not a prognostic factor in patient with mCRC treated with either REG or TFTD as later-line. No difference in OS was observed between REG and TFTD groups irrespective of PTL.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 105)

Abstract #

105

Poster Bd #

E13

Abstract Disclosures